Mauricio Ribeiro

12PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologySolid tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Nov 11, 2025
Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.

Vincent Rondeau, Suraj Bansal, Marco M Buttigieg

|Aug 13, 2025
Prognostic and Predictive Value of ctDNA for Metastatic Uveal Melanoma: A Systematic Review and Meta-Analysis.

Mariana Macambira Noronha, Luís Felipe Leite da Silva, Luiz Felipe Costa Almeida

|May 15, 2024
Clinical activity of pembrolizumab in refractory MDM2-amplified advanced intimal sarcomas.

Mauricio Fernando Ribeiro, Elizabeth G Demicco, Albiruni Ryan Abdul Razak

|Dec 23, 2023
The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies.

Seth Kibel, Nathan Kuehne, Mauricio Fernando Ribeiro

|Oct 02, 2023
Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study.

Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura

|Sep 09, 2023
Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre.

Erica C Koch Hein, Maysa Vilbert, Ian Hirsch

Pageof 2

Frequent Collaborators

4 joint publications

Artur Katz

3 joint publications

Marcus O Butler

3 joint publications

Erick F Saldanha

2 joint publications

Samuel D Saibil